Express News | Halozyme Announces argenx Received Positive Chmp Opinion for Vyvgart® (Efgartigimod Alfa) Subcutaneous Injection With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $72
Express News | HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target
Halozyme: Outcome of This Dispute Will Not Impact ENHANZE >HALO
Halozyme Is Seeking Damages and Injunctive Relief
Express News | Halozyme Sues Merck for Patent Infringement Over Subcutaneous Keytruda Formulation
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
Express News | JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $58
Halozyme Therapeutics Analyst Ratings
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
Peering Into Halozyme Therapeutics's Recent Short Interest
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx
Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma
Express News | European Commission Approved Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
European Commission Approved Subcutaneous DARZALEX (Daratumumab)-based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
Morgan Stanley Lists 'Attractive' Small-cap Stocks With Positive ROE and Momentum
Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU
Halozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of...
Express News | European Commission Approves Subcutaneous Rybrevant® (Amivantamab) Co-Formulated With Enhanze® for the Treatment of Patients With Advanced Egfr-Mutated Non-Small Cell Lung Cancer